• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era-getting nearer?

作者信息

Verstockt Bram, Ferrante Marc

机构信息

Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.

KU Leuven Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium.

出版信息

Aliment Pharmacol Ther. 2020 Apr;51(7):737-738. doi: 10.1111/apt.15634.

DOI:10.1111/apt.15634
PMID:32162373
Abstract
摘要

相似文献

1
Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era-getting nearer?
Aliment Pharmacol Ther. 2020 Apr;51(7):737-738. doi: 10.1111/apt.15634.
2
Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era-getting nearer? Authors' reply.社论：一种用于识别在生物时代可能从强化给药中获益最大的患者的临床决策工具——即将实现？作者回复
Aliment Pharmacol Ther. 2020 Apr;51(7):738-739. doi: 10.1111/apt.15671.
3
Editorial: the road to elimination of viral hepatitis-another promising real-world experience.社论：消除病毒性肝炎之路——又一次充满希望的现实世界经验。
Aliment Pharmacol Ther. 2020 Jul;52(2):405-406. doi: 10.1111/apt.15837.
4
THE APPROVAL OF VEDOLIZUMAB FOR THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES IN BRAZIL: the beginning of a new biological era.
Arq Gastroenterol. 2016 Jan-Mar;53(1):3-4. doi: 10.1590/S0004-28032016000100002.
5
Editorial: drug monitoring targets for optimising adalimumab in Crohn's disease.社论：优化克罗恩病中阿达木单抗治疗效果的药物监测目标
Aliment Pharmacol Ther. 2014 Oct;40(7):854-5. doi: 10.1111/apt.12911.
6
Editorial: accumulating data about ustekinumab in refractory Crohn's disease in real world experience.社论：在真实世界经验中积累关于乌司奴单抗治疗难治性克罗恩病的数据。
Aliment Pharmacol Ther. 2017 May;45(10):1374-1375. doi: 10.1111/apt.14053.
7
Editorial: ustekinumab and Crohn's disease-what can we learn from long-term extension studies?社论：优特克单抗与克罗恩病——我们能从长期扩展研究中学到什么？
Aliment Pharmacol Ther. 2018 Aug;48(3):382-383. doi: 10.1111/apt.14844.
8
Editorial: adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease.社论：阿达木单抗剂量递增对控制克罗恩病继发的反应丧失有效。
Aliment Pharmacol Ther. 2014 Nov;40(10):1249. doi: 10.1111/apt.12966.
9
Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn's disease.英夫利昔单抗和阿达木单抗连续停用后重新使用英夫利昔单抗治疗难治性克罗恩病的效果
Inflamm Bowel Dis. 2014 Feb;20(2):251-8. doi: 10.1097/01.MIB.0000438248.14218.1d.
10
Natalizumab for induction of remission in Crohn's disease.那他珠单抗用于诱导克罗恩病缓解
Cochrane Database Syst Rev. 2006 Jul 19(3):CD006097. doi: 10.1002/14651858.CD006097.

引用本文的文献

1
Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises.炎症性肠病中用于个性化治疗选择的生物标志物发现：挑战与前景。
Curr Res Pharmacol Drug Discov. 2022 Jan 26;3:100089. doi: 10.1016/j.crphar.2022.100089. eCollection 2022.
2
Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study.维得利珠单抗治疗炎症性肠病患者的临床经验及治疗成功的预测因素：一项队列研究
BMC Gastroenterol. 2021 Jan 22;21(1):33. doi: 10.1186/s12876-021-01604-z.